A recent review article by Schots et al., published in Frontiers in Pharmacology, investigates how the different constituents of Calanus® Oil can contribute to the prevention of obesity-induced low-grade inflammation and the associated metabolic disturbances. Calanus® Oil is a natural oil derived from the 1-year copepod Calanus finmarchicus. In addition to having the unique wax ester form, Calanus® Oil is not refined and therefore contains a broad range of nutrients.
The publication summarizes knowledge of common omega-3 fatty acids like EPA and DHA, and in addition how Stearidonic acid, monounsaturated fatty acids, policosanols and astaxanthin can contribute to the metabolic and inflammatory health in a favourable way.
Head of Science in Calanus AS, Alice Marie Pedersen, PhD, says: “This publication is the first comprehensive review that evaluates the different bioactive constituents of Calanus® Oil. Even if there is still much to discover, there is already existing knowledge on for instance policosanols and monounsaturated fatty acids, which are associated with the Mediterranean diet.”
The researchers also conclude that the wax esters likely act as natural delayed release molecules, thereby facilitating transportation of fatty acids to the GPR120 receptors (also known as FFA4 receptor). The fatty acids act as potent stimulators of the GPR120 receptor, which is associated with reduced inflammation, improved insulin sensitivity and enhanced glucose uptake. GPR120 is a target for treatment of obesity and type 2 diabetes.
Dr. Pedersen concludes: “Stearidonic acid is also extremely interesting, and it is likely that this special fatty acid, as a part of the wax ester molecule, could explain many of the benefits we have observed in research and among consumers.”
Calanus® Oil is an omega-3 rich oil, where the fatty acid’s special chemistry gives additional benefits in the metabolic health area. Recent research has shown a favourable impact on body composition, insulin sensitivity and heart pumping efficiency. Calanus® Oil is currently being sold in Europe and North America, with several regulatory approval processes ongoing in other markets.
For further information please contact Head of Sales and Marketing Jan Erik Olsen on tel. +47 951 45 351 or by e-mail: email@example.com. Please also refer to the company’s website: www.calanus.no.
Link to the original press release including downloadable scientific poster, pictures and other material: Mynewsdesk.com
Calanus AS is a biomarine company pioneering harvesting and utilization of the crustacean Calanus finmarchicus, and is well positioned to play a key role in industrialization of the entire value chain through its intellectual property rights. Calanus AS develops functional health- and nutrition ingredients for humans and animals exclusively from this valuable raw material. The Company’s main product is Calanus® Oil, an ecologically sustainable marine oil for humans. Calanus® Oil has unique composition and has shown benefits like improved insulin sensitivity, reduced deposition of intra-abdominal fat and powerful anti-inflammatory effects.